Preloader

Signatera™ & Lattitude

Signatera™ + Latitude™: FDA-approved precision in MRD monitoring.

Signatera™ is a highly sensitive, tumor-informed Minimal Residual Disease (MRD) assay. By analyzing circulating tumor DNA (ctDNA) in blood, it helps detect the risk of recurrence at an early stage, monitor treatment response, and support clinical decision-making. Signatera™ is an FDA-approved MRD assay and is recommended by international clinical guidelines for multiple tumor types, including colorectal cancer, breast cancer, and non-small cell lung cancer.

Why Signatera™?

  • Assessment of treatment response during the neoadjuvant setting
  • Determination of the need for adjuvant therapy
  • Early detection of molecular recurrence
  • Monitoring of treatment response and disease management
  • Support for optimized clinical decision-making

When Is Signatera™ Used?

Signatera - Minimal Residual Disease (MRD)

 Signatera Exome™Signatera Genome™Latitude™
Cancer TypeAll Solid Tumors (Colorectal, Breast, Lung, Bladder, etc.)All Solid Tumors (Colorectal, Breast, Lung, Bladder, etc.)Colorectal Cancer (CRC) Only
MethodologyWES-Based Signatera™ mPCR-NGSWGS-Based Signatera™ mPCR-NGSTissue-Free DNA Methylation-Based MRD Analysis
Number of Variants16 Clonal Variants64 Clonal VariantsEpigenomic Biomarker-Based Analysis
Sequencing Depth~100,000× Ultra-Deep SequencingUp to 350,000× Ultra-Deep SequencingTargeted Methylation-Based Analysis
Setup RequirementsFFPE Tumor Tissue + 1 EDTA Blood Tube + 2 Streck Blood TubesFFPE Tumor Tissue + 2 EDTA Blood Tubes + 2 Streck Blood TubesNo tumor tissue required. Setup requires 1 EDTA Blood Tube and 2 Streck Blood Tubes.
Follow-Up Sample Requirements2 Streck Blood Tubes2 Streck Blood Tubes2 Streck Blood Tubes
Turnaround Time (Setup)4–5 Weeks4 Weeks
Turnaround Time (Follow-Up)7–10 Days7–10 Days<14 Days
Key AdvantagePersonalized, Tumor-Informed MRD AnalysisUltra-High Sensitivity Personalized MRD Analysis with Strong Detection Performance Even at Very Low ctDNA LevelsRapid and Convenient MRD Assessment Without Requiring Tumor Tissue

*For patients with colorectal cancer (CRC), Latitude™ can be performed using a plasma sample only, without the need for tumor tissue.

 
//
Our customer support team is here to answer your questions!